GlassScriptPhysician profile
Dipti L Bhoiwala
NPI 1750515961
$13,111.68
in general payments reported to CMS, 2019-2025
36 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $904 · 2021: $2,140 · 2022: $1,585 · 2023: $1,802 · 2024: $2,655 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373 · Education: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.86 |
| Education | $487.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,822.12 | 2019-2025 | Tremfya, Simponi Aria, Acclarent Navwire |
| Astrazeneca Pharmaceuticals LP | $2,765.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,060.41 | 2020-2025 | Linzess, Vraylar, Creon |
| Amgen INC. | $1,110.14 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $675.70 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Novo Nordisk INC | $616.50 | 2019-2024 | Ozempic, Rybelsus |
| Aimmune Therapeutics, INC. | $543.36 | 2024-2025 | Zenpep |
| Ucb, INC. | $405.82 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $398.17 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $370.71 | 2022-2024 | Acthar |
| Biohaven Pharmaceuticals, INC. | $202.74 | 2020-2021 | |
| Allergan, INC. | $199.69 | 2019-2020 | |
| Lilly USA, LLC | $96.15 | 2021-2025 | Mounjaro, Zepbound, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.50 | 2021-2023 | Jardiance |
| Abbott Laboratories | $85.57 | 2022-2023 | Freestyle Libre 2 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $74.88 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.19 | 2019 | |
| Grifols USA, LLC | $70.98 | 2023-2024 | Xembify, Gamunex-C |
| Nestle Healthcare Nutrition INC. | $65.40 | 2023 | |
| Eisai INC. | $47.00 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $38.64 | 2021 | |
| Redhill Biopharma INC. | $33.38 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $31.41 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $30.52 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.42 | 2022 | |
| Vivus LLC | $24.85 | 2022 | |
| Pharming Healthcare, INC. | $20.72 | 2023 | Ruconest |
| Indivior INC. | $19.49 | 2019 | |
| Argenx US, INC. | $17.13 | 2025 | Vyvgart Hytrulo |
| Philips North America LLC | $17.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $16.23 | 2024 | Arcalyst |
| Biohaven Pharmaceutical Holding Company LTD. | $14.91 | 2022 | |
| Axsome Therapeutics, INC. | $14.05 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $13.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.48 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipti Bhoiwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.